Baseline characteristics of patients requiring TAVI (n=217)
| mean±SD, median (IQR) or n (%) | mean±SD, median (IQR) or % | ||
| Age (years) | 82 (78–86) | Log ES I | 20.1% (13.6–32.6) |
| Male | 96 (44.2%) | ≤20% | 107 (49.3%) |
| BMI (kg/m2) | 26.2 (23.7–29.1) | >20% | 110 (50.7%) |
| NYHA classification | ES II | 6.1% (3.8–10.3) | |
| I | 9 (4.2%) | ||
| II | 61 (28.1%) | ||
| III | 122 (56.2%) | NTproBNP (pg/mL) | 2094 (932–4970.5) |
| IV | 25 (11.5%) | ||
| AFIB/AFLUT | 97 (44.7%) | ||
| Significant CAD | 161 (74.2%) | ||
| Previous cardiac surgery | 87 (40.1%) | ||
| COPD | 39 (18.0%) | ||
| Diabetes | 64 (29.5%) | Osteopontin (ng/mL) | 675 (488.5–990.5) |
| Dyslipidaemia | 108 (49.8%) | ||
| Hypertension | 197 (90.8%) | ||
| Peripheral vascular disease | 86 (25.4%) | EF | |
| Cerebrovascular disease | 33 (15.2%) | <35% | 25 (11.5%) |
| GFR | 35%–45% | 42 (19.4%) | |
| <30 mL/min | 11 (5.1%) | 46%–54% | 41 (18.9%) |
| 30–45 mL/min | 49 (22.6%) | ≥55% | (50.2%) |
| 45–60 mL/min | 106 (48.9%) | Systolic pulmonary hypertension | 42 (34–53) |
| >60 mL/min | 51 (23.5%) | <35 mm Hg | (29.5%) |
| STS PROM score | 5.2% (3.5–7.8) | 35–59 mm Hg | (58.5%) |
| ≤10% | 190 (87.6%) | >59 mm Hg | (17.1%) |
| >10% | 27 (12.4%) | Aortic valve area (cm2) | 0.7 (0.6–0.8) |
| AR≥2, invasive | (24.9%) |
AFIB, atrial fibrillation; AFLUT, atrial flutter; AR, aortic regurgitation; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; ES II, EuroSCORE II; GFR, glomerular filtration rate; Log ES, logistic EuroSCORE; NTproBNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.